Affimed NV
Buy, Hold or Sell?
Let's analyze Affimed together
I guess you are interested in Affimed NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Affimed NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Affimed NV
I send you an email if I find something interesting about Affimed NV.
1. Quick Overview
1.1. Quick analysis of Affimed (30 sec.)
1.2. What can you expect buying and holding a share of Affimed? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Affimed (5 min.)
2.2. Growth of Affimed (5 min.)
Is Affimed growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $30.3m | $140.5m | -$94.4m | -204.8% |
How much money is Affimed making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$19.6m | -$28.8m | $9.2m | 46.8% |
Net Profit Margin | -8,419.6% | -1,162.8% | - | - |
How much money comes from the company's main activities?
2.3. Financial Health of Affimed (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Affimed?
Welcome investor! Affimed's management wants to use your money to grow the business. In return you get a share of Affimed.
First you should know what it really means to hold a share of Affimed. And how you can make/lose money.
Speculation
The Price per Share of Affimed is $2.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Affimed.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Affimed, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.94. Based on the TTM, the Book Value Change Per Share is $-1.18 per quarter. Based on the YOY, the Book Value Change Per Share is $1.32 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | -1.04 | -37.5% | -1.25 | -45.1% | -1.76 | -63.5% | -1.00 | -36.1% | -0.78 | -28.0% |
Usd Book Value Change Per Share | 0.00 | 0.0% | -1.18 | -42.6% | 1.32 | 47.5% | -0.01 | -0.5% | 0.22 | 7.9% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% |
Usd Total Gains Per Share | 0.00 | 0.0% | -1.18 | -42.6% | 1.32 | 47.5% | -0.01 | -0.5% | 0.22 | 7.9% |
Usd Price Per Share | 5.45 | - | 2.96 | - | 1.16 | - | 3.64 | - | 3.88 | - |
Price to Earnings Ratio | -1.31 | - | -0.69 | - | -0.20 | - | -0.48 | - | -0.97 | - |
Price-to-Total Gains Ratio | -2.38 | - | -0.22 | - | 3.44 | - | -1.26 | - | ||
Price to Book Ratio | 2.82 | - | 1.47 | - | 0.12 | - | 1.48 | - | 1.44 | - |
Price-to-Total Gains Ratio | -2.38 | - | -0.22 | - | 3.44 | - | -1.26 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 2.78 |
Number of shares | 359 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | -1.18 | -0.01 |
Usd Total Gains Per Share | -1.18 | -0.01 |
Gains per Quarter (359 shares) | -424.81 | -5.00 |
Gains per Year (359 shares) | -1,699.24 | -20.00 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | -1699 | -1709 | 0 | -20 | -30 |
2 | 0 | -3398 | -3408 | 0 | -40 | -50 |
3 | 0 | -5098 | -5107 | 0 | -60 | -70 |
4 | 0 | -6797 | -6806 | 0 | -80 | -90 |
5 | 0 | -8496 | -8505 | 0 | -100 | -110 |
6 | 0 | -10195 | -10204 | 0 | -120 | -130 |
7 | 0 | -11895 | -11903 | 0 | -140 | -150 |
8 | 0 | -13594 | -13602 | 0 | -160 | -170 |
9 | 0 | -15293 | -15301 | 0 | -180 | -190 |
10 | 0 | -16992 | -17000 | 0 | -200 | -210 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 12.0 | 0.0 | 0.0% | 1.0 | 19.0 | 0.0 | 5.0% | 5.0 | 35.0 | 0.0 | 12.5% | 6.0 | 40.0 | 1.0 | 12.8% |
Book Value Change Per Share | 0.0 | 3.0 | 1.0 | 0.0% | 2.0 | 8.0 | 2.0 | 16.7% | 7.0 | 11.0 | 2.0 | 35.0% | 14.0 | 24.0 | 2.0 | 35.0% | 15.0 | 27.0 | 5.0 | 31.9% |
Dividend per Share | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 12.0 | 0.0% | 0.0 | 0.0 | 20.0 | 0.0% | 0.0 | 0.0 | 40.0 | 0.0% | 0.0 | 0.0 | 47.0 | 0.0% |
Total Gains per Share | 0.0 | 3.0 | 1.0 | 0.0% | 2.0 | 8.0 | 2.0 | 16.7% | 7.0 | 11.0 | 2.0 | 35.0% | 14.0 | 24.0 | 2.0 | 35.0% | 15.0 | 27.0 | 5.0 | 31.9% |
3.2. Key Performance Indicators
The key performance indicators of Affimed NV compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | - | -1.183 | 0% | 1.321 | -100% | -0.014 | 0% | 0.219 | -100% |
Book Value Per Share | - | - | 1.936 | 2.941 | -34% | 8.964 | -78% | 5.078 | -62% | 4.025 | -52% |
Current Ratio | - | - | 2.710 | 3.045 | -11% | 5.353 | -49% | 3.484 | -22% | 5.234 | -48% |
Debt To Asset Ratio | - | - | 0.460 | 0.427 | +8% | 0.251 | +84% | 0.447 | +3% | 0.357 | +29% |
Debt To Equity Ratio | - | - | 0.852 | 0.754 | +13% | 0.335 | +154% | 0.982 | -13% | 0.736 | +16% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -1.042 | -1.254 | +20% | -1.764 | +69% | -1.005 | -4% | -0.777 | -25% |
Free Cash Flow Per Share | - | - | -1.114 | -1.320 | +18% | -1.974 | +77% | -1.049 | -6% | -0.619 | -44% |
Free Cash Flow To Equity Per Share | - | - | -1.031 | -1.313 | +27% | -2.079 | +102% | -0.570 | -45% | -0.143 | -86% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% |
Intrinsic Value_10Y_max | - | - | -16.219 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -59.138 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -2.355 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -6.315 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -6.519 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -18.750 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -10.013 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -30.843 | - | - | - | - | - | - | - | - |
Market Cap | 43592624.000 | -96% | 85460360.000 | 46465738.580 | +84% | 18204624.760 | +369% | 104105706.107 | -18% | 84312178.853 | +1% |
Net Profit Margin | - | - | -100.331 | -84.196 | -16% | -11.628 | -88% | -20.672 | -79% | -17.097 | -83% |
Operating Margin | - | - | - | -58.001 | 0% | -11.358 | 0% | -15.331 | 0% | -14.688 | 0% |
Operating Ratio | - | - | 102.357 | 86.556 | +18% | 12.865 | +696% | 21.961 | +366% | 4551812205.107 | -100% |
Pb Ratio | 1.436 | -96% | 2.815 | 1.469 | +92% | 0.123 | +2196% | 1.484 | +90% | 1.444 | +95% |
Pe Ratio | -0.667 | +49% | -1.308 | -0.693 | -47% | -0.197 | -85% | -0.481 | -63% | -0.969 | -26% |
Price Per Share | 2.780 | -96% | 5.450 | 2.963 | +84% | 1.161 | +369% | 3.642 | +50% | 3.878 | +41% |
Price To Free Cash Flow Ratio | -0.624 | +49% | -1.223 | -0.648 | -47% | -0.174 | -86% | 2.060 | -159% | -0.483 | -60% |
Quick Ratio | - | - | 1.816 | 3.715 | -51% | 5.128 | -65% | 3.508 | -48% | 5.516 | -67% |
Return On Assets | - | - | -0.291 | -0.264 | -9% | -0.169 | -42% | -0.142 | -51% | -0.120 | -59% |
Return On Equity | - | - | -0.538 | -0.467 | -13% | -0.228 | -58% | -0.272 | -50% | -0.199 | -63% |
Total Gains Per Share | - | - | - | -1.183 | 0% | 1.321 | -100% | -0.014 | 0% | 0.219 | -100% |
Usd Book Value | - | - | 30353569.400 | 46118894.525 | -34% | 140559944.250 | -78% | 93467672.045 | -68% | 70039693.295 | -57% |
Usd Book Value Change Per Share | - | - | - | -1.183 | 0% | 1.321 | -100% | -0.014 | 0% | 0.219 | -100% |
Usd Book Value Per Share | - | - | 1.936 | 2.941 | -34% | 8.964 | -78% | 5.078 | -62% | 4.025 | -52% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -1.042 | -1.254 | +20% | -1.764 | +69% | -1.005 | -4% | -0.777 | -25% |
Usd Free Cash Flow | - | - | -17471748.800 | -20702510.675 | +18% | -30961401.900 | +77% | -16976761.725 | -3% | -9964356.738 | -43% |
Usd Free Cash Flow Per Share | - | - | -1.114 | -1.320 | +18% | -1.974 | +77% | -1.049 | -6% | -0.619 | -44% |
Usd Free Cash Flow To Equity Per Share | - | - | -1.031 | -1.313 | +27% | -2.079 | +102% | -0.570 | -45% | -0.143 | -86% |
Usd Market Cap | 43592624.000 | -96% | 85460360.000 | 46465738.580 | +84% | 18204624.760 | +369% | 104105706.107 | -18% | 84312178.853 | +1% |
Usd Price Per Share | 2.780 | -96% | 5.450 | 2.963 | +84% | 1.161 | +369% | 3.642 | +50% | 3.878 | +41% |
Usd Profit | - | - | -16333252.100 | -19670516.800 | +20% | -28882879.025 | +77% | -19096458.645 | +17% | -12418520.098 | -24% |
Usd Revenue | - | - | 162793.400 | 640866.875 | -75% | 7617991.150 | -98% | 6247091.015 | -97% | 4628723.770 | -96% |
Usd Total Gains Per Share | - | - | - | -1.183 | 0% | 1.321 | -100% | -0.014 | 0% | 0.219 | -100% |
EOD | +2 -5 | MRQ | TTM | +13 -14 | YOY | +13 -18 | 5Y | +5 -22 | 10Y | +6 -25 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -0.667 | |
Price to Book Ratio (EOD) | Between | 0-1 | 1.436 | |
Net Profit Margin (MRQ) | Greater than | 0 | -100.331 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 1.816 | |
Current Ratio (MRQ) | Greater than | 1 | 2.710 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.460 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.852 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.538 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.291 | |
Total | 4/10 (40.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Open | Greater than | Close | 2.850 | |
Total | 1/1 (100.0%) |
4. In-depth Analysis
4.1 About Affimed NV
- https://www.affimed.com
- Biotechnology
- 76
- Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
Google Maps Bing Maps
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Fundamental data was last updated by Penke on 2024-11-14 09:24:04.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is underpriced. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Affimed to the Biotechnology industry mean.
- A Net Profit Margin of -10,033.1% means that $-100.33 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Affimed NV:
Trends
- The YOY is -1,162.8%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -2,067.2%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -1,709.7%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -10,033.1% | TTM | -8,419.6% | -1,613.5% | |
TTM | -8,419.6% | YOY | -1,162.8% | -7,256.8% | |
TTM | -8,419.6% | 5Y | -2,067.2% | -6,352.4% | |
5Y | -2,067.2% | 10Y | -1,709.7% | -357.5% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -112.2%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -221.4%. trending down. -2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Affimed to the Biotechnology industry mean.
- -29.1% Return on Assets means that Affimed generated $-0.29 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Affimed NV:
Trends
- The YOY is -16.9%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -14.2%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -12.0%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -29.1% | TTM | -26.4% | -2.7% | |
TTM | -26.4% | YOY | -16.9% | -9.4% | |
TTM | -26.4% | 5Y | -14.2% | -12.2% | |
5Y | -14.2% | 10Y | -12.0% | -2.2% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.3%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.7%. trending down. -2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Affimed to the Biotechnology industry mean.
- -53.8% Return on Equity means Affimed generated $-0.54 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Affimed NV:
Trends
- The YOY is -22.8%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -27.2%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -19.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -53.8% | TTM | -46.7% | -7.1% | |
TTM | -46.7% | YOY | -22.8% | -23.9% | |
TTM | -46.7% | 5Y | -27.2% | -19.5% | |
5Y | -27.2% | 10Y | -19.9% | -7.3% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -14.2%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -15.9%. trending down. -2
4.3.2. Operating Efficiency of Affimed NV.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Affimed makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Affimed to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Affimed NV:
- The MRQ is 0.0%. The data is not here.
Trends
- The YOY is -1,135.8%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -1,533.1%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -1,468.8%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | -5,800.1% | +5,800.1% | |
TTM | -5,800.1% | YOY | -1,135.8% | -4,664.2% | |
TTM | -5,800.1% | 5Y | -1,533.1% | -4,267.0% | |
5Y | -1,533.1% | 10Y | -1,468.8% | -64.3% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -222.9%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -310.7%. trending down. -2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 102.36 means that the operating costs are $102.36 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Affimed NV:
Trends
- The YOY is 12.865. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 21.961. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 4,551,812,205.107. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 102.357 | TTM | 86.556 | +15.801 | |
TTM | 86.556 | YOY | 12.865 | +73.691 | |
TTM | 86.556 | 5Y | 21.961 | +64.595 | |
5Y | 21.961 | 10Y | 4,551,812,205.107 | -4,551,812,183.146 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.465. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 3.253. trending up. -2
4.4.3. Liquidity of Affimed NV.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 2.71 means the company has $2.71 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Affimed NV:
Trends
- The YOY is 5.353. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 3.484. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 5.234. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 2.710 | TTM | 3.045 | -0.334 | |
TTM | 3.045 | YOY | 5.353 | -2.309 | |
TTM | 3.045 | 5Y | 3.484 | -0.440 | |
5Y | 3.484 | 10Y | 5.234 | -1.749 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.637. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.890. trending down. -2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Affimed to the Biotechnology industry mean.
- A Quick Ratio of 1.82 means the company can pay off $1.82 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Affimed NV:
Trends
- The YOY is 5.128. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 3.508. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 5.516. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.816 | TTM | 3.715 | -1.899 | |
TTM | 3.715 | YOY | 5.128 | -1.412 | |
TTM | 3.715 | 5Y | 3.508 | +0.207 | |
5Y | 3.508 | 10Y | 5.516 | -2.008 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.086. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.451. trending up. +2
4.5.4. Solvency of Affimed NV.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Affimed to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.46 means that Affimed assets are financed with 46.0% credit (debt) and the remaining percentage (100% - 46.0%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Affimed NV:
Trends
- The YOY is 0.251. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.447. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.357. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.460 | TTM | 0.427 | +0.033 | |
TTM | 0.427 | YOY | 0.251 | +0.177 | |
TTM | 0.427 | 5Y | 0.447 | -0.020 | |
5Y | 0.447 | 10Y | 0.357 | +0.090 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.350. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.344. trending up. -2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Affimed to the Biotechnology industry mean.
- A Debt to Equity ratio of 85.2% means that company has $0.85 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Affimed NV:
Trends
- The YOY is 0.335. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.982. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.736. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.852 | TTM | 0.754 | +0.098 | |
TTM | 0.754 | YOY | 0.335 | +0.419 | |
TTM | 0.754 | 5Y | 0.982 | -0.228 | |
5Y | 0.982 | 10Y | 0.736 | +0.246 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.394. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.432. trending up. -2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Affimed to the Biotechnology industry mean.
- A PE ratio of -1.31 means the investor is paying $-1.31 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Affimed NV:
Trends
- The YOY is -0.197. Compared to the TTM, the mid term is trending down. +2
- The 5Y is -0.481. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -0.969. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -0.667 | MRQ | -1.308 | +0.641 | |
MRQ | -1.308 | TTM | -0.693 | -0.615 | |
TTM | -0.693 | YOY | -0.197 | -0.496 | |
TTM | -0.693 | 5Y | -0.481 | -0.212 | |
5Y | -0.481 | 10Y | -0.969 | +0.488 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.403. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.148. trending up. -2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Affimed NV:
- The EOD is -0.624. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -1.223. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -0.648. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -0.174. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 2.060. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -0.483. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -0.624 | MRQ | -1.223 | +0.599 | |
MRQ | -1.223 | TTM | -0.648 | -0.575 | |
TTM | -0.648 | YOY | -0.174 | -0.474 | |
TTM | -0.648 | 5Y | 2.060 | -2.708 | |
5Y | 2.060 | 10Y | -0.483 | +2.544 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.234. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.719. trending up. -2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 2.82 means the investor is paying $2.82 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Affimed NV:
Trends
- The YOY is 0.123. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 1.484. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 1.444. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 1.436 | MRQ | 2.815 | -1.379 | |
MRQ | 2.815 | TTM | 1.469 | +1.347 | |
TTM | 1.469 | YOY | 0.123 | +1.346 | |
TTM | 1.469 | 5Y | 1.484 | -0.016 | |
5Y | 1.484 | 10Y | 1.444 | +0.040 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.051. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.356. trending down. +2
4.6.2. Total Gains per Share
4.7 Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Affimed NV.
4.8.1. Institutions holding Affimed NV
Institutions are holding 36.656% of the shares of Affimed NV.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-06-30 | 683 Capital Management LLC | 4.1452 | 0.2677 | 650000 | -19998 | -2.9848 |
2024-06-30 | Morgan Stanley - Brokerage Accounts | 3.5687 | 0.0001 | 559606 | 305706 | 120.4041 |
2024-06-30 | NEA Management Company, LLC | 2.8229 | 0.1815 | 442649 | 0 | 0 |
2024-06-30 | Millennium Management LLC | 2.3774 | 0.0009 | 372788 | 350806 | 1595.8784 |
2024-06-30 | Point72 Asset Management, L.P. | 2.0901 | 0.0047 | 327748 | -94834 | -22.4416 |
2024-06-30 | Eversept Partners, LLC | 1.0616 | 0.0621 | 166460 | 0 | 0 |
2024-06-30 | Verition Fund Managegment, LLC | 0.8424 | 0.0039 | 132087 | 50453 | 61.8039 |
2024-06-30 | Vanguard Group Inc | 0.8262 | 0 | 129560 | 0 | 0 |
2024-06-30 | BNP Paribas Arbitrage, SA | 0.5476 | 0.0004 | 85866 | 13282 | 18.2988 |
2024-06-30 | Intellectus Partners, LLC | 0.5364 | 0.1251 | 84111 | 40897 | 94.6383 |
2024-06-30 | State Street Corp | 0.3513 | 0 | 55088 | 1038 | 1.9204 |
2024-06-30 | Walleye Trading Advisors, LLC | 0.1537 | 0.0002 | 24106 | 24106 | 0 |
2024-06-30 | Commonwealth Equity Services Inc | 0.1377 | 0.0002 | 21590 | 0 | 0 |
2024-09-30 | abrdn PLC | 0.133 | 0.0001 | 20862 | 0 | 0 |
2024-06-30 | Jump Financial LLC | 0.1131 | 0.0019 | 17733 | 17733 | 0 |
2024-06-30 | BlackRock Inc | 0.1038 | 0 | 16283 | -662 | -3.9068 |
2024-06-30 | Clayton Financial Group LLC | 0.0957 | 0.0344 | 15000 | 0 | 0 |
2024-06-30 | FMR Inc | 0.0868 | 0 | 13610 | 612 | 4.7084 |
2024-06-30 | Geode Capital Management, LLC | 0.0867 | 0 | 13594 | 0 | 0 |
2024-06-30 | EWA, LLC | 0.0792 | 0.0268 | 12421 | -1435 | -10.3565 |
Total | 20.1595 | 0.71 | 3161162 | +687704 | +21.8% |
4.9.2. Funds holding Affimed NV
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-09-30 | Vanguard Explorer Inv | 0.4825 | 0.0011 | 75667 | 0 | 0 |
2024-09-30 | Vanguard VIF Small Co Gr | 0.3437 | 0.0116 | 53893 | 0 | 0 |
2024-09-30 | abrdn Life Sciences Investors | 0.133 | 0.0152 | 20862 | 0 | 0 |
2024-09-30 | DFA US Targeted Value I | 0.1119 | 0.0004 | 17545 | 14054 | 402.5781 |
2024-09-30 | Fidelity Nasdaq Composite Index | 0.0469 | 0.0001 | 7351 | 0 | 0 |
2024-08-31 | Fidelity VIP Disciplined Small Cap Init | 0.0285 | 0.0043 | 4468 | 0 | 0 |
2024-09-30 | JNL/DFA US Small Cap A | 0.0037 | 0.0003 | 575 | 0 | 0 |
2024-08-31 | Guggenheim Active Allocation Fund | 0.0004 | 0 | 69 | 0 | 0 |
2024-05-31 | Nationwide Multi-Cap Portfolio R6 | 0.0004 | 0 | 66 | 0 | 0 |
Total | 1.151 | 0.033 | 180496 | +14054 | +7.8% |
5. Financial Statements
5.1. Latest Balance Sheet
Balance Sheet of 2024-06-30. Currency in EUR. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 24,460 |
Total Stockholder Equity | + 28,714 |
Total Assets | = 53,174 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 7,969 |
Intangible Assets | 18 |
Long-term Assets (as reported) | 7,987 |
---|---|
Long-term Assets (calculated) | 7,987 |
+/- | 0 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long term Debt | 3,603 |
Capital Lease Obligations Min Short Term Debt | 5,079 |
Long-term Liabilities (as reported) | 7,788 |
---|---|
Long-term Liabilities (calculated) | 8,682 |
+/- | 894 |
Total Stockholder Equity
Total Stockholder Equity (as reported) | 28,714 |
---|---|
Total Stockholder Equity (calculated) | 0 |
+/- | 28,714 |
Other
Capital Stock | 1,568 |
Common Stock Shares Outstanding | 15,681 |
Net Invested Capital | 38,150 |
Net Working Capital | 28,515 |
Property Plant and Equipment Gross | 7,969 |
5.2. Balance Sheets Structured
Currency in EUR. All numbers in thousands.
Trend | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 53,174 | 53,174 | 70,553 | 120,464 | 134,711 | 134,711 | 200,512 | 236,399 | 260,905 | 193,251 | 225,135 | 220,335 | 248,023 | 175,725 | 175,725 | 107,938 | 101,148 | 112,359 | 112,359 | 85,550 | 99,117 | 110,339 | 116,174 | 49,069 | 59,515 | 66,589 | 43,158 | 45,356 | 53,219 | 57,044 | 48,739 | 53,235 | 61,642 | 70,600 | 79,322 | 63,131 | 69,824 | 39,290 | 41,909 | 47,860 | 4,510 | 7,047 | 6,500 | 0 | 0 | 0 | 9,482 | |||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 45,187 | 45,187 | 62,157 | 106,829 | 130,836 | 130,836 | 196,070 | 230,550 | 254,791 | 180,930 | 206,394 | 203,271 | 227,186 | 150,799 | 150,799 | 101,392 | 95,069 | 105,914 | 105,914 | 79,530 | 92,487 | 104,325 | 110,879 | 40,146 | 50,677 | 58,226 | 41,980 | 44,180 | 52,154 | 56,161 | 47,862 | 52,326 | 60,680 | 69,595 | 78,335 | 62,111 | 68,861 | 38,291 | 40,863 | 46,665 | 3,442 | 5,849 | 5,292 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 10,764 | 10,764 | 14,348 | 62,817 | 120,056 | 120,056 | 190,286 | 222,895 | 237,232 | 169,850 | 197,630 | 198,742 | 222,676 | 146,854 | 146,854 | 89,656 | 84,584 | 95,234 | 95,234 | 59,995 | 63,987 | 63,089 | 94,829 | 37,076 | 47,412 | 55,339 | 39,837 | 33,343 | 44,486 | 49,007 | 35,407 | 35,693 | 40,603 | 49,181 | 76,740 | 60,425 | 66,319 | 37,033 | 39,725 | 45,546 | 1,800 | 5,044 | 4,151 | 0 | 0 | 0 | 6,464 | |||||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 24,561 | 24,561 | 35,027 | 34,659 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7,687 | 8,037 | 8,902 | 8,902 | 16,530 | 23,726 | 32,043 | 13,974 | 0 | 0 | 0 | 0 | 8,470 | 4,381 | 4,676 | 9,487 | 13,440 | 18,015 | 17,567 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 5,717 | 5,717 | 6,038 | 2,446 | 2,154 | 2,154 | 2,697 | 1,691 | 5,524 | 4,547 | 4,809 | 3,759 | 3,763 | 2,439 | 2,439 | 2,552 | 2,027 | 1,482 | 1,482 | 1,184 | 1,471 | 8,298 | 1,429 | 1,443 | 1,024 | 1,812 | 1,102 | 1,583 | 2,524 | 2,275 | 2,255 | 2,337 | 1,147 | 1,923 | 915 | 1,447 | 2,320 | 1,057 | 939 | 932 | 1,469 | 667 | 1,001 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
| 4,145 | 4,145 | 6,044 | 6,098 | 7,932 | 7,932 | 2,459 | 760 | 7,407 | 6,048 | 3,534 | 78 | 135 | 1,260 | 1,260 | 1,087 | 0 | 0 | 8,902 | 1,491 | 2,973 | 570 | 387 | 1,307 | 1,974 | 813 | 800 | 502 | 513 | 12 | 516 | 603 | 682 | 682 | 452 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 7,987 | 7,987 | 8,396 | 13,635 | 3,875 | 3,875 | 4,442 | 5,849 | 6,114 | 12,321 | 18,741 | 17,064 | 20,837 | 24,926 | 24,926 | 6,546 | 6,079 | 6,445 | 6,445 | 6,020 | 6,630 | 6,014 | 5,295 | 8,923 | 8,838 | 8,363 | 1,178 | 1,176 | 1,065 | 883 | 877 | 909 | 962 | 1,005 | 987 | 1,020 | 963 | 999 | 1,046 | 1,195 | 1,068 | 1,198 | 1,208 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 7,969 | 7,969 | 8,374 | 13,594 | 3,829 | 3,829 | 4,384 | 4,294 | 4,561 | 4,567 | 4,786 | 4,226 | 4,483 | 3,166 | 3,166 | 3,389 | 2,773 | 3,115 | 3,115 | 2,577 | 2,613 | 2,009 | 1,414 | 1,271 | 1,230 | 1,168 | 1,113 | 1,120 | 1,004 | 828 | 822 | 845 | 897 | 932 | 915 | 959 | 899 | 929 | 974 | 1,044 | 907 | 968 | 1,034 | 0 | 0 | 0 | 1,615 | |||||||||||||||||||||||||||||||||||||||||||||||
Long Term Investments |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6,174 | 12,348 | 11,204 | 14,693 | 18,789 | 20,042 | 3,064 | 3,203 | 3,274 | 3,193 | 3,294 | 3,849 | 3,898 | 13,149 | 13,631 | 8,771 | 8,771 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets |
| 18 | 18 | 25 | 0 | 0 | 0 | 58 | 0 | 0 | 0 | 1,607 | 0 | 0 | 1,718 | 1,718 | 93 | 103 | 137 | 137 | 149 | 168 | 107 | 56 | 63 | 72 | 65 | 65 | 56 | 61 | 55 | 55 | 64 | 65 | 73 | 72 | 61 | 64 | 70 | 72 | 96 | 116 | 145 | 158 | 0 | 0 | 0 | 343 | |||||||||||||||||||||||||||||||||||||||||||||||
Long-term Assets Other |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,553 | 1,580 | 0 | 1,634 | 1,661 | 0 | 0 | 0 | 0 | 0 | 6,445 | 6,020 | 6,630 | 6,014 | 0 | 11 | -36 | -30 | 0 | 0 | -100 | -100 | -100 | 0 | -100 | 0 | 0 | -100 | -100 | 0 | -100 | 0 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 24,460 | 24,460 | 29,890 | 44,044 | 35,785 | 35,785 | 47,597 | 55,296 | 68,085 | 75,831 | 89,184 | 86,478 | 97,144 | 103,732 | 103,732 | 60,922 | 60,646 | 73,692 | 73,692 | 63,317 | 66,272 | 67,684 | 76,045 | 13,221 | 12,334 | 12,327 | 11,579 | 11,549 | 13,085 | 9,452 | 9,988 | 10,036 | 9,082 | 10,841 | 12,048 | 9,409 | 9,472 | 8,637 | 10,114 | 10,078 | 106,025 | 121,916 | 105,723 | 0 | 0 | 0 | 105,904 | |||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 16,672 | 16,672 | 20,315 | 28,887 | 25,888 | 25,888 | 34,651 | 40,828 | 52,008 | 57,795 | 64,547 | 66,291 | 67,157 | 67,027 | 67,027 | 45,180 | 32,491 | 35,181 | 35,181 | 29,153 | 26,565 | 32,937 | 36,843 | 10,977 | 9,465 | 8,845 | 7,493 | 6,867 | 7,801 | 6,152 | 6,371 | 8,351 | 6,954 | 8,332 | 8,944 | 5,968 | 5,135 | 4,129 | 6,219 | 6,408 | 15,490 | 22,389 | 14,940 | 0 | 0 | 0 | 2,722 | |||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 0 | 6,882 | 6,805 | 6,538 | 6,123 | 6,123 | 6,326 | 5,498 | 4,111 | 2,631 | 1,263 | 760 | 616 | 584 | 584 | 1,849 | 1,490 | 2,637 | 2,637 | 3,297 | 3,929 | 3,417 | 3,083 | 3,083 | 3,083 | 3,083 | 3,083 | 2,500 | 1,750 | 1,389 | 973 | 1,959 | 2,149 | 1,920 | 1,472 | 932 | 0 | 0 | 3,759 | 131 | 5,153 | 4,976 | 4,800 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 5,833 | 5,833 | 5,833 | 5,898 | 5,923 | 5,930 | 5,930 | 4,957 | 3,498 | 2,039 | 580 | 94 | 93 | 92 | 92 | 1,070 | 1,039 | 1,401 | 2,105 | 2,960 | 3,552 | 3,083 | 10,598 | 5,538 | 3,588 | 3,793 | 3,083 | 2,500 | 7,034 | 4,689 | 973 | 0 | 0 | 0 | 1,472 | 0 | 0 | 0 | 3,895 | 0 | 0 | 22,352 | 82,745 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 9,171 | 9,171 | 12,891 | 21,713 | 15,810 | 15,810 | 19,077 | 15,078 | 12,760 | 13,537 | 18,860 | 13,716 | 15,838 | 11,394 | 7,986 | 8,123 | 6,606 | 10,674 | 10,674 | 7,633 | 7,541 | 6,289 | 9,425 | 7,253 | 5,926 | 5,307 | 4,180 | 4,334 | 5,793 | 4,536 | 5,323 | 6,327 | 4,698 | 4,711 | 4,444 | 4,879 | 4,563 | 3,113 | 3,759 | 4,996 | 3,404 | 4,012 | 3,862 | 0 | 0 | 0 | 2,300 | |||||||||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 0 | 0 | 0 | 636 | 3,955 | 0 | 0 | 20,252 | 35,137 | 41,627 | 46,199 | 51,815 | 50,703 | 50,920 | 58,457 | 479 | 484 | 517 | 517 | 1,131 | 1,440 | 65,112 | 86,894 | 1,151 | 531 | 560 | 1,239 | 39 | 294 | 243 | 941 | 73 | 118 | 1,937 | 4,049 | 35 | 638 | 1,091 | 3,759 | 1,618 | 4,875 | 11,242 | 6,196 | 0 | 0 | 0 | 422 | |||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 7,788 | 7,788 | 9,575 | 15,157 | 9,897 | 9,897 | 12,946 | 14,468 | 16,077 | 18,036 | 24,637 | 20,187 | 29,987 | 36,705 | 36,705 | 15,742 | 28,155 | 38,511 | 38,511 | 34,164 | 39,707 | 34,747 | 39,202 | 2,244 | 2,869 | 3,482 | 4,086 | 4,682 | 5,284 | 3,300 | 3,617 | 1,685 | 2,128 | 2,509 | 3,104 | 3,441 | 4,337 | 4,508 | 3,895 | 3,670 | 90,535 | 99,527 | 90,783 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Long term Debt Total |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 409 | 550 | 492 | 569 | 1,259 | 5,065 | 3,482 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 5,079 | -1,610 | 394 | 976 | -5,800 | -5,675 | -5,754 | -4,754 | -3,181 | -1,751 | -212 | 220 | 508 | 648 | 390 | -738 | -944 | -1,960 | -1,833 | -2,768 | -3,306 | -2,781 | -3,083 | -3,083 | -3,083 | -3,083 | -3,083 | -2,500 | -1,750 | -1,389 | -973 | -1,959 | -2,149 | -1,920 | -1,472 | -932 | 0 | 0 | -3,759 | -131 | -5,153 | -4,976 | -4,800 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 28,714 | 28,714 | 40,663 | 76,420 | 98,926 | 98,926 | 152,915 | 181,103 | 192,820 | 117,420 | 135,951 | 133,857 | 150,879 | 71,993 | 71,993 | 47,016 | 40,502 | 38,667 | 38,667 | 22,233 | 32,845 | 42,655 | 40,129 | 35,848 | 47,181 | 54,262 | 31,579 | 33,807 | 40,134 | 47,592 | 38,751 | 43,199 | 52,560 | 59,759 | 67,274 | 53,722 | 60,352 | 30,653 | 31,795 | 37,782 | -101,515 | -114,869 | -99,223 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Retained Earnings | -570,754 | -570,754 | -555,303 | -515,923 | -491,568 | -491,568 | -430,190 | -392,826 | -372,290 | -350,062 | -333,397 | -310,309 | -293,214 | -275,874 | -275,874 | -261,001 | -255,035 | -234,508 | -234,508 | -221,516 | -210,632 | -200,292 | -202,144 | -210,904 | -198,884 | -190,870 | -182,667 | -176,246 | -168,146 | -160,199 | -152,444 | -147,022 | -136,727 | -128,690 | -120,228 | -113,949 | -106,657 | -101,473 | -99,989 | -94,689 | -102,022 | -115,376 | -99,730 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income |
| 0 | 597,900 | 594,443 | 590,850 | 589,001 | 589,001 | 581,612 | 572,436 | 563,617 | 466,248 | 468,114 | 442,968 | 442,896 | 346,884 | 346,884 | 307,134 | 294,692 | 272,413 | 272,413 | 243,125 | 242,853 | 242,323 | 241,649 | 246,128 | 245,441 | 244,508 | 213,778 | 209,606 | 207,841 | 207,352 | 190,862 | 189,888 | 188,954 | 188,116 | 187,169 | 167,372 | 166,710 | 131,886 | 131,544 | 132,231 | 469 | 469 | 469 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34 | 0 | -34 | 0 | 0 | 0 | -33 |
5.3. Balance Sheets
Currency in EUR. All numbers in thousands.
5.4. Cash Flows
Currency in EUR. All numbers in thousands.
5.5. Income Statements
Currency in EUR. All numbers in thousands.